Disclosed herein are immunoglobulin fusion proteins comprising a first immunoglobulin region attached to a therapeutic peptide at the amino terminus of the immunoglobulin region. The immunoglobulin fusion proteins may further comprise a second immunoglobulin region. The immunoglobulin fusion protein may further comprise one or more connecting peptides, linkers, proteolytic cleavage sites, internal linkers, or a combination thereof. The immunoglobulin fusion proteins may further comprise one or more additional therapeutic peptides. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent.

The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability.

Methods of inducing bradycardia (slowing a heart rate) in a subject in need thereof, treating a medical condition in which inducing bradycardia (slowing a heart rate) is desirable or beneficial in a subject in need thereof and/or treating a medical condition associated with cardiac arrhythmia, are provided. The methods are effected by blocking SK4 channel in SAN cell of the subject and/or by administering to the subject a therapeutically effective amount of a blocker of an SK4 channel. A method of identifying candidate compounds for treating an arrhythmic cardiac disorder, by identifying compounds that reduce a pacing rate of the SAN cells is also provided.

Methods of inducing bradycardia (slowing a heart rate) in a subject in need thereof, treating a medical condition in which inducing bradycardia (slowing a heart rate) is desirable or beneficial in a subject in need thereof and/or treating a medical condition associated with cardiac arrhythmia, are provided. The methods are effected by blocking SK4 channel in SAN cell of the subject and/or by administering to the subject a therapeutically effective amount of a blocker of an SK4 channel. A method of identifying candidate compounds for treating an arrhythmic cardiac disorder, by identifying compounds that reduce a pacing rate of the SAN cells is also provided.

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Compositions for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or intestinal hypoperfusion are provided.

Provided herein are compositions and methods for treating heart disease. In particular, provided herein are constructs, devices, and systems, each comprising one or more placenta-derived compositions, and their use in treating disorders involving aberrant cardiac rhythms and promoting repair of damaged cardiac tissue. The method of treatment comprises applying one or more constructs on the surface of all or a portion of the heart and/or adjacent tissues, during or after surgical heart treatment.

Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.

Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets than whole blood. Concentrations of lymphocytes, monocytes, and neutrophils may be different from concentrations found in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue, particularly spinal disc, and/or to slow or stop cardiac apoptosis after a heart attack.

The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.